Pharmacodynamics of CGT 2168 Compared With Plavix®

Inclusion Criteria: * Healthy males and females. Women of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use two methods of effective barrier contraception, or a hormonal contraceptive to prevent pregnancy throughout the study. * Able to comply with study procedures, which includes returning to the Phase I unit for all scheduled visits and procedures. * Abstinence from tobacco use (including smoking cessation products containing nicotine) for 90 days prior to study entry, with agreement to abstain from tobacco/nicotine use throughout the study. * Agreement to abstain from alcohol and caffeine ingestion from 72 h before dosing and throughout each dosing period. * Able to give informed consent, and subject has signed and dated a written consent form approved by the IRB. Exclusion Criteria: * Hypersensitivity to clopidogrel, omeprazole, or related drugs including inactive ingredients. * BMI (body mass index) outside the range of 19-30 kg/m2. * At screening, body weight less than 50 kg if male or 45 kg if female. * Clinically significant abnormal findings on physical examination, clinical laboratory tests or ECG at screening. * History of hypertension or 5-minute sitting screening BP ≥160/100 mmHg on measurements repeated twice. * History of diabetes mellitus, renal failure, acute or chronic liver disease, including acute or chronic hepatitis, or cirrhosis. * Positive HIV-1 antibody, hepatitis B surface antigen or hepatitis C antibody screening test. * History of any clinically significant medical or psychiatric condition. * Difficulty in swallowing medication, or any known or suspected gastrointestinal abnormality that may affect drug absorption. * Participation in a previous clinical trial within 30 days prior to enrollment (check-in on Day -1 for Visit 2). * Blood donation of ≥ 1 pint within 30 days or plasma donation within 14 days prior to enrollment (check-in on Day -1 for Visit 2). * Use of any prescription or over-the-counter medications or ingestion of herbal drugs/dietary supplements including vitamins and minerals within 14 days prior to enrollment (check-in on Day -1 for Visit 2). Hormonal contraceptives are allowed. * Subject is not willing to refrain from drinking grapefruit juice or eating grapefruit throughout study participation. * Subject is an active illicit drug user or has a history of illicit drug use within the previous 12 months.